Silverberg JI, Strober B, Feinstein B, Xu J, et al. Efficacy and safety of rademikibart (CBP-201), a next-generation monoclonal antibody targeting IL-4Ralpha, in adults with moderate-to-severe atopic dermatitis: a phase 2 randomized trial (CBP-201-WW001). J Allergy Clin Immunol 2023 Dec 27:S0091-6749(23)02546.
PMID: 38157942